medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Number 4

<< Back Next >>

Ann Hepatol 2018; 17 (4)

Rapamycin Combi with TAE on the Growth, Metastasis, and Prognosis of Hepatocellular Carcinoma in Rat Models

Lei Hong-Wei, Cai J, Li Cheng-Ming, Yang F, Shi Wan-Qing, Wang Li-Ping, Feng You-Ying

Language: English
References: 37
Page: 645-654
PDF size: 664.73 Kb.


ABSTRACT

Introduction and aim. To investigate the effect of mTOR inhibitor Rapamycin combined with transcatheter arterial embolization (TAE) on the growth, metastasis, and prognosis of hepatocellular carcinoma (HCC) in rat model. Material and method. McARH7777 cells were used to construct rat models of HCC, which were randomly divided into Model, Rapamycin, TAE, and Rapamycin + TAE groups. Quantitative reverse transcription-PCR (qRT-PCR) and Western Blot were used to detect the expression of Epithelial-Mesenchymal Transition (EMT)-related molecules, and immunohistochemical staining to determine the expression of EMTrelated proteins, angiogenic factors as well as microvessel density (MVD)-CD34. Results. The hepatic tumor volume of rats in the other three groups were all significantly smaller than the Model group on the 7th, 14th, and 21st day after treatment and the combination treatment was apparently more effective than either treatment alone. Besides, both the number and the size of metastatic nodules of HCC rats after combination treatment were remarkably reduced. In addition, compared with rats in the Rapamycin + TAE group, N-cadherin, Vimentin, HIF-1 α, VEGF, and MVD-CD34 were obviously enhanced, while E-cadherin was lowered in those TAE group, which were the complete opposite to the Rapamycin group. Besides, the median survival time of rats in the Rapamycin + TAE group was evidently longer than the resting groups. Conclusion. Rapamycin combined with TAE may effectively suppress the EMT formation and angiogenesis, thereby inhibiting the growth and lung metastasis of HCC rats, which provides a new idea for countering the recurrence and metastasis of HCC.


REFERENCES

  1. Tang B, Tang F, Wang Z, Qi G, Liang X, Li B, Yuan S, et al. Upregulation of Akt/NF-kappaB-regulated inflammation and Akt/Bad-related apoptosis signaling pathway involved in hepatic carcinoma process: suppression by carnosic acid nanoparticle. Int J Nanomedicine 2016; 11: 6401-20. 10.2147/ IJN.S101285

  2. Liu L, Zhao Y, Jia J, Chen H, Bai W, Yang M, Yin Z, et al. The Prognostic Value of Alpha-Fetoprotein Response for Advanced- Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization. Sci Rep 2016; 6: 19851. 10.1038/srep19851

  3. Goseki N, Nosaka T, Endo M, Koike M. Nourishment of hepatocellular carcinoma cells through the portal blood flow with and without transcatheter arterial embolization. Cancer 1995; 76: 736-42.

  4. Taniguchi K, Nakata K, Kato Y, Sato Y, Hamasaki K, Tsuruta S, Nagataki S. Treatment of hepatocellular carcinoma with transcatheter arterial embolization. Analysis of prognostic factors. Cancer 1994; 73: 1341-5.

  5. Acunas B, Rozanes I. Hepatocellular carcinoma: treatment with transcatheter arterial chemoembolization. Eur J Radiol 1999; 32: 86-9.

  6. Dai F, Zhang X, Shen W, Chen J, Liu L, Gao G. Liposomal curcumin inhibits hypoxia-induced angiogenesis after transcatheter arterial embolization in VX2 rabbit liver tumors. Onco Targets Ther 2015; 8: 2601-11. 10.2147/OTT.S87931

  7. Zhao H, Ahirwar DK, Oghumu S, Wilkie T, Powell CA, Nasser MW, Satoskar AR, et al. Endothelial Robo4 suppresses breast cancer growth and metastasis through regulation of tumor angiogenesis. Mol Oncol 2016; 10: 272-81. 10.1016/ j.molonc.2015.10.007

  8. Nitta-Seko A, Nitta N, Sonoda A, Otani H, Tsuchiya K, Ohta S, Takahashi M, et al. Anti-tumour effects of transcatheter arterial embolisation administered in combination with thalidomide in a rabbit VX2 liver tumour model. Br J Radiol 2011; 84: 179-83. 10.1259/bjr/53771502

  9. Wei K, Wang M, Zhang W, Mu H, Song TQ. Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib. Med Oncol 2014; 31: 969. 10.1007/s12032-014- 0969-5

  10. Wang C, Yu JT, Miao D, Wu ZC, Tan MS, Tan L. Targeting the mTOR signaling network for Alzheimer’s disease therapy. Mol Neurobiol 2014; 49: 120-35. 10.1007/s12035-013- 8505-8

  11. Liu F, Zhang W, Yang F, Feng T, Zhou M, Yu Y, Yu X, et al. Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling. Sci Rep 2016; 6: 21260. 10.1038/ srep21260

  12. Mabuchi S, Kuroda H, Takahashi R, Sasano T. The PI3K/AKT/ mTOR pathway as a therapeutic target in ovarian cancer. Figure 7. Effects of Rapamycin combined with TAE on the survival of HCC rats. Gynecol Oncol 2015; 137: 173-9. 10.1016/j.ygyno.2015. 02.003

  13. Zhao Q, Wang Z, Wang Z, Wu L, Zhang W. Aspirin may inhibit angiogenesis and induce autophagy by inhibiting mTOR signaling pathway in murine hepatocarcinoma and sarcoma models. Oncol Lett 2016; 12: 2804-10. 10.3892/ol.2016.5017

  14. Xue ZG, Niu PG, Shi DH, Liu Y, Deng J, Chen YY. Cardamonin Inhibits Angiogenesis by mTOR Downregulation in SKOV3 Cells. Planta Med 2016; 82: 70-5. 10.1055/s-0035-1557901

  15. Huo Y, Iadevaia V, Proud CG. Differing effects of rapamycin and mTOR kinase inhibitors on protein synthesis. Biochem Soc Trans 2011; 39: 446-50. 10.1042/BST0390446

  16. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128- 35. 10.1038/nm0202-128

  17. Sekiguchi Y, Zhang J, Patterson S, Liu L, Hamada C, Tomino Y, Margetts PJ. Rapamycin inhibits transforming growth factor beta-induced peritoneal angiogenesis by blocking the secondary hypoxic response. J Cell Mol Med 2012; 16: 1934-45. 10.1111/j.1582-4934.2011.01493.x

  18. Xie J, Wang X, Proud CG. mTOR inhibitors in cancer therapy. F1000Res. 2016; 5:10.12688/f1000research.9207.1

  19. Yuan R, Kay A, Berg WJ, Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009; 2: 45. 10.1186/1756-8722-2-45

  20. Owonikoko TK. Inhibitors of mTOR pathway for cancer therapy, moving on from rapalogs to TORKinibs. Cancer 2015; 121: 3390-2. 10.1002/cncr.29424

  21. Orlans FB. Ethical decision making about animal experiments. Ethics Behav 1997; 7: 163-71. 10.1207/ s15327019eb0702_7

  22. Futakuchi M, Hirose M, Ogiso T, Kato K, Sano M, Ogawa K, Shirai T. Establishment of an in vivo highly metastatic rat hepatocellular carcinoma model. Jpn J Cancer Res 1999; 90: 1196-202.

  23. Zhang Q, Chen X, Zhou J, Zhang L, Zhao Q, Chen G, Xu J, et al. CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients. Cancer Biol Ther 2006; 5: 808-14.

  24. Rossi A, Pica-Mattoccia L, Cioli D, Klinkert MQ. Rapamycin insensitivity in Schistosoma mansoni is not due to FKBP12 functionality. Mol Biochem Parasitol 2002; 125: 1-9.

  25. Fuentes EN, Einarsdottir IE, Paredes R, Hidalgo C, Valdes JA, Bjornsson BT, Molina A. The TORC1/P70S6K and TORC1/ 4EBP1 signaling pathways have a stronger contribution on skeletal muscle growth than MAPK/ERK in an early vertebrate: Differential involvement of the IGF system and atrogenes. Gen Comp Endocrinol 2015; 210: 96-106. 10.1016/ j.ygcen.2014.10.012

  26. Song X, Dilly AK, Kim SY, Choudry HA, Lee YJ. Rapamycinenhanced mitomycin C-induced apoptotic death is mediated through the S6K1-Bad-Bak pathway in peritoneal carcinomatosis. Cell Death Dis 2014; 5:e1281. 10.1038/cddis. 2014.242

  27. Cifarelli V, Lashinger LM, Devlin KL, Dunlap SM, Huang J, Kaaks R, Pollak MN, et al. Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms. Diabetes 2015; 64: 1632-42. 10.2337/db14-1132

  28. Neef M, Ledermann M, Saegesser H, Schneider V, Reichen J. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol 2006; 45: 786-96. 10.1016/j.jhep.2006.07.030

  29. Willatt JM, Francis IR, Novelli PM, Vellody R, Pandya A, Krishnamurthy VN. Interventional therapies for hepatocellular carcinoma. Cancer Imaging 2012; 12: 79-88. 10.1102/ 1470-7330.2012.0011

  30. Liu K, Min XL, Peng J, Yang K, Yang L, Zhang XM. The Changes of HIF-1alpha and VEGF Expression After TACE in Patients With Hepatocellular Carcinoma. J Clin Med Res 2016; 8: 297-302. 10.14740/jocmr2496w

  31. Rhee TK, Young JY, Larson AC, Haines GK, 3rd, Sato KT, Salem R, Mulcahy MF, et al. Effect of transcatheter arterial embolization on levels of hypoxia-inducible factor-1alpha in rabbit VX2 liver tumors. J Vasc Interv Radiol 2007; 18: 639- 45. 10.1016/j.jvir.2007.02.031

  32. Li W, Zong S, Shi Q, Li H, Xu J, Hou F. Hypoxia-induced vasculogenic mimicry formation in human colorectal cancer cells: Involvement of HIF-1a, Claudin-4, and E-cadherin and Vimentin. Sci Rep 2016; 6: 37534. 10.1038/srep37534

  33. Ye Z, Zhou M, Tian B, Wu B, Li J. Expression of lncRNACCAT1, E-cadherin and N-cadherin in colorectal cancer and its clinical significance. Int J Clin Exp Med 2015; 8: 3707-15.

  34. Fang ZT, Wang GZ, Zhang W, Qu XD, Liu R, Qian S, Zhu L, et al. Transcatheter arterial embolization promotes liver tumor metastasis by increasing the population of circulating tumor cells. Onco Targets Ther 2013; 6: 1563-72. 10.2147/ OTT.S52973

  35. Xiang S, Li M, Xie X, Xie Z, Zhou Q, Tian Y, Lin W, et al. Rapamycin inhibits epithelial-to-mesenchymal transition of peritoneal mesothelium cells through regulation of Rho GTPases. FEBS J 2016; 283: 2309-25. 10.1111/febs.13740

  36. Tang J, Wang J, Fan L, Li X, Liu N, Luo W, Wang J, et al. cRGD inhibits vasculogenic mimicry formation by down-regulating uPA expression and reducing EMT in ovarian cancer. Oncotarget 2016; 7: 24050-62. 10.18632/oncotarget.8079

  37. Huang M, Ke Y, Sun X, Yu L, Yang Z, Zhang Y, Du M, et al. Mammalian target of rapamycin signaling is involved in the vasculogenic mimicry of glioma via hypoxia-inducible factor- 1alpha. Oncol Rep 2014; 32: 1973-80. 10.3892/ or.2014.3454




2020     |     www.medigraphic.com